467 related articles for article (PubMed ID: 27089415)
1. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
Eldeeb K; Leone-Kabler S; Howlett AC
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
[TBL] [Abstract][Full Text] [Related]
2. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.
Glass M; Felder CC
J Neurosci; 1997 Jul; 17(14):5327-33. PubMed ID: 9204917
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid receptor interacting protein (CRIP1a) attenuates CB1R signaling in neuronal cells.
Blume LC; Eldeeb K; Bass CE; Selley DE; Howlett AC
Cell Signal; 2015 Mar; 27(3):716-726. PubMed ID: 25446256
[TBL] [Abstract][Full Text] [Related]
4. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.
Calandra B; Portier M; Kernéis A; Delpech M; Carillon C; Le Fur G; Ferrara P; Shire D
Eur J Pharmacol; 1999 Jun; 374(3):445-55. PubMed ID: 10422789
[TBL] [Abstract][Full Text] [Related]
5. Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor.
Bosier B; Hermans E; Lambert D
Br J Pharmacol; 2008 Sep; 155(1):24-33. PubMed ID: 18536748
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs.
Abadji V; Lucas-Lenard JM; Chin C; Kendall DA
J Neurochem; 1999 May; 72(5):2032-8. PubMed ID: 10217281
[TBL] [Abstract][Full Text] [Related]
7. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulation.
Smith TH; Blume LC; Straiker A; Cox JO; David BG; McVoy JR; Sayers KW; Poklis JL; Abdullah RA; Egertová M; Chen CK; Mackie K; Elphick MR; Howlett AC; Selley DE
Mol Pharmacol; 2015 Apr; 87(4):747-65. PubMed ID: 25657338
[TBL] [Abstract][Full Text] [Related]
9. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
[TBL] [Abstract][Full Text] [Related]
10. The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity.
Turu G; Simon A; Gyombolai P; Szidonya L; Bagdy G; Lenkei Z; Hunyady L
J Biol Chem; 2007 Mar; 282(11):7753-7. PubMed ID: 17227758
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
12. Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs.
Obadiah J; Avidor-Reiss T; Fishburn CS; Carmon S; Bayewitch M; Vogel Z; Fuchs S; Levavi-Sivan B
Cell Mol Neurobiol; 1999 Oct; 19(5):653-64. PubMed ID: 10384262
[TBL] [Abstract][Full Text] [Related]
13. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.
Shen CP; Xiao JC; Armstrong H; Hagmann W; Fong TM
Eur J Pharmacol; 2006 Feb; 531(1-3):41-6. PubMed ID: 16438957
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells.
Vanhauwe JF; Fraeyman N; Francken BJ; Luyten WH; Leysen JE
J Pharmacol Exp Ther; 1999 Aug; 290(2):908-16. PubMed ID: 10411608
[TBL] [Abstract][Full Text] [Related]
15. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?
Kearn CS; Blake-Palmer K; Daniel E; Mackie K; Glass M
Mol Pharmacol; 2005 May; 67(5):1697-704. PubMed ID: 15710746
[TBL] [Abstract][Full Text] [Related]
16. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent.
Caballero-Florán RN; Conde-Rojas I; Oviedo Chávez A; Cortes-Calleja H; Lopez-Santiago LF; Isom LL; Aceves J; Erlij D; Florán B
Neuropharmacology; 2016 Nov; 110(Pt A):407-418. PubMed ID: 27506997
[TBL] [Abstract][Full Text] [Related]
18. G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
Newman-Tancredi A; Cussac D; Audinot V; Pasteau V; Gavaudan S; Millan MJ
Mol Pharmacol; 1999 Mar; 55(3):564-74. PubMed ID: 10051542
[TBL] [Abstract][Full Text] [Related]
19. Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors.
Ross RA; Gibson TM; Stevenson LA; Saha B; Crocker P; Razdan RK; Pertwee RG
Br J Pharmacol; 1999 Oct; 128(3):735-43. PubMed ID: 10516656
[TBL] [Abstract][Full Text] [Related]
20. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
